Kansas Gov. Kathleen Sebelius fills HHS secretary post, while Tennessee health commissioner Nancy Ann DeParle fills director of the White House Office for Health Reform.
President Obama nominated Kansas Governor Kathleen Sebelius for the post of secretary of Health and Human Services (HHS) and previous Tennessee health commissioner Nancy Ann DeParle for the post of director of the White House Office for Health Reform.
Sebelius was Obama’s second choice after Tom Daschle, who withdrew from the nomination after it was revealed that he owed more than $120,000 in federal taxes. Daschle had been pegged to run both HHS and the White House Office for Health Reform.
DeParle was previously Tennessee’s commissioner of the Department of Human Services, handling budgets for Medicare and Medicaid in the Clinton administration.In a press conference, Obama stated, “Healthcare reform that reduces costs while expanding coverage is no longer just a dream we hope to achieve; it’s a necessity we have to achieve.”
Andrea Pennington, MD, chief medical officer, Logical Images, based in Rochester, NY, and former medical director for Discovery Health Channel, believes that Sebelius brings significant experience and political savvy to the table.
“To her credit, her managerial expertise as Governor for Kansas has afforded her valuable direct experience with Medicaid,” Dr. Pennington says. “Though she hasn't always enjoyed success while in office-she failed to get health coverage extended to children through age five and was unsuccessful in passing a cigarette tax increase for the expansion of Medicaid-most are confident that she will do well working with President Obama due to a history of bipartisan administration. And, once she effectively takes the helm, I believe she will quickly dispel myths about being the ‘back-up’ plan since Daschle’s withdrawal from consideration.”
Managed care executives can expect that as Secretary of HHS, Sebelius will reinforce Obama’s accountability mantra. “Her record shows that she’s got the guts to fight for the underdog and will root out waste and mismanagement,” Dr. Pennington says.
Elizabeth Hall, vice president, public policy for WellPoint says that WellPoint looks forward to working with the two nominees “and will continue to work with the Congress and the administration to improve healthcare quality, control health spending and build on the current private-public system to put America on the path to healthcare coverage for everyone.”
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More